• JUser::_load: Unable to load user with id: 8375


  • Home
    Home This is where you can find all the blog posts throughout the site.
  • Categories
    Categories Displays a list of categories from this blog.
  • Tags
    Tags Displays a list of tags that has been used in the blog.
  • Bloggers
    Bloggers Search for your favorite blogger from this site.
  • Team Blogs
    Team Blogs Find your favorite team blogs here.
  • Login
Recent blog posts

RALEIGH, N.C. -- Startup TechWire ( has launched to champion entrepreneurs and innovation.


The professional news outlet reports on business, innovation, and education for America's vibrant startup community, especially the life sciences.


“The number of entrepreneurs across the U.S. is constantly growing, but not everybody is hearing about all the new tech that’s out there. It’s exciting to help build a stronger innovation community by sharing news and information on these startups and the businesses that support them,” David Menzies, editor/publisher, said.


Nearly a fifth of working adults in the U.S. – approximately 27 million people – identify as entrepreneurs. Many of these are solopreneurs, running a business alone without employees in order to stay lean and nimble to adapt to change, although this is somewhat limiting to scalability.


Many of these solopreneurs, Menzies explained, do not have the resources to get their stories out.


“That’s one of the ways Startup TechWire can help, by showcasing their products and ideas as well as covering trends related to their technologies,” he said.


Larger entrepreneurial trends in 2016 include innovation in utility apps geared toward “real life” issues such as travel, health and fitness, music, and news; bots and artificial intelligence; and products that promote productivity.


Menzies originally began publishing the tech news website as a means to generate extra visibility and web traffic for clients of his PR consultancy, Innovative Public Relations. Peers in the PR field began asking him if they could send their clients’ news items, and the publication grew, with Menzies utilizing his years of experience as a print newspaper editor to cull submissions and put forth a professional publication.


Word of mouth generated interest beyond the publication’s initial focus on North and South Carolina, with Startup TechWire now covering the entire U.S.


Fresh, original articles and user-submitted news items are updated daily, complimented by feeds from respected media sources.


Startup TechWire is an extraordinarily powerful and effective means of reaching a great number of people locally, nationally and globally.


For more information on editorial and advertising opportunities, visit or email This e-mail address is being protected from spambots. You need JavaScript enabled to view it .


About Startup TechWire

Startup TechWire ( reports on business, innovation, and education for America's vibrant startup community. It is a professionally edited online news outlet providing readers with timely information about the life sciences, entrepreneurism, high tech and education. Fresh, original articles and user-submitted news items are updated daily, complimented by feeds from respected media sources. Startup TechWire is published by Innovative Public Relations, Inc., a publicity and branding consultancy helping clients achieve their business development and organizational goals. All content is edited by Editor/Publisher David Menzies 919-274-6862 ( an award-winning 22-year professional communicator, published author and former print newspaper editor with a rich technology background.


Tagged in: bio innovation news
Hits: 1650

By Jason Bissessur

Supple and smooth skin in our early youth can mirror the ‘ageless’ glow of clear vitality until after a while when ‘ageing’ nooks and crannies start to kick in.

Environmental culprits on the skin such as adverse weather and pollution can leave our sensitive coats looking dryer and duller by the day. But over time skin can reveal more grisly surprises on its surface, most commonly Thread Veins (aka ‘Spider’ veins for a more scare mongering term), a condition that affects 1 in 3 men and women.

Although the exact cause is not known with experts who speculate factors such as changing hormones and extreme weather conditions, there are readily available treatments that can lessen the impact of these ‘bulging’ dark veins.

This takes us swiftly onto the rejuvenating ‘holy grail’ science of IPL (Intense Pulsed Light) Thread Vein Removal, a procedure that beams intense rays of light directly onto the surface of these thread veins. Without damaging any surrounding tissue, the exposing heavy light causes blood inside the veins to dry and harden, making them absorbed naturally by the body and hence the result of a less visible appearance onto the skin.  Voila!

With such intense treatment, some might even wonder what does it feels like to have these dark spider-like veins vanquished. In fact, people that have undergone the procedure have experienced a warm prickly pin feeling or ‘tingly’ sensation when light is beamed onto their skin, but is pleasantly tolerable throughout.

For best results, it is recommended to have at least 4 treatments for every area affected by thread veins, leaving ideally 3 weeks in-between treatments to notice the effects. It’s a straightforward no brainer due to its remarkable simplicity, that can be done in 1 hour after work and back in time next day to the office!

As you know all treatments come with its own potential side effects, but these are rare but worth knowing anyways. Don’t fear! The chances you getting these is little as the likelihood of getting squished by the moon!

Side Effects may include:

-Burning where the area of thread veins is treated

-Blistering where the area of thread veins is treated

-Swelling where the area of thread veins is treated


However ‘scary’ these side effects may seem, it’s very rare and if you do get any of these reported symptoms, it will certainly heal over time!

Tagged in: aging anti-aging tip
Hits: 1703

Posted by on in Health

Antioxidants aid in protecting skin cells against collagen-degrading enzymes so skin looks less wrinkled. They also counteract free radicals thus help reduce damage caused by strenuous exercise, harmful chemicals, and UV radiation.

Studies show that a blend of anti-oxidants are more effective than single anti-oxidants used alone.

Hits: 1220

Posted by on in Uncategorized
Hits: 224

Posted by on in Health

Normal 0 false false false EN-IN X-NONE X-NONE

Learn the thorough medical definition of lochia at What is Lochia? - Adidarwinian


Hits: 1327

Posted by on in Uncategorized
Hits: 328

Posted by on in Health

P { margin-bottom: 0.08in; direction: ltr; color: rgb(0, 0, 0); }P.western { font-family: "Liberation Serif","Times New Roman",serif; font-size: 12pt; }P.cjk { font-family: "WenQuanYi Micro Hei"; font-size: 12pt; }P.ctl { font-family: "Lohit Hindi"; font-size: 12pt; }A:link { }

The Medical Academy of Pediatric Special Needs (MAPS) is going to organize the MAPS Spring Conference 2015, from March 12-14, 2015, in Hilton Orange County, Costa Mesa. The 3-day conference will provide Clinician CME Training in fields of special needs children and Autism Spectrum Disorders (ASD). The conference aims to educate medical professionals about scientific medical conditions in kids with ASD.

The conference invites:

  • Medical Doctors (MD)

  • Doctor of Chiropractic (DC)

  • Doctor of Osteopathic Medicine (DO)

  • Naturopathic Doctor (ND)

  • Physicians Assistant (PA)

  • Registered Nurse (RN)

  • Nurse Practitioner (NP)

  • Certified Clinical Nutritionist (CCN)

  • Registered Pharmacist (Rph)

  • Pharmacist (PharmD)

  • Psychologists with Doctorate (PsyD)

  • And other nutrition and healthcare providers




Leading scientists and medical practitioners are going to share their knowledge in the conference as speakers. The knowledge offered by these experts will reach beyond typical lecture series. They will put forth working case studies, and evidence supporting the treatment of certain conditions.


The honorable speakers of the MAPS Spring Conference 2015 are:

  • Dr. Sidney Baker

  • David Berger, MD (MAPS Faculty)

  • Jeff Bradstreet, M.D., M.D.(H), FAAFP, FMAPS

  • Dr. David Dornfeld

  • Stuart Freedenfeld, MD

  • Dr. Richard Frye

  • Dr. Suzanne Goh

  • Jerry Kartzinel, MD

  • Vicki Kobliner

  • Arthur Krigsman, MD

  • Elizabeth Mumper, MD, FAAFP

  • Dr. Nancy O’Hara

  • Dr. Dan Rossignol (MAPS President)

  • Dr. Cindy Schneider

  • Dr. Anju Usman

  • Dr. Vincent, MD

  • Dr. Robert K. Naviaux, MD, PhD


Topics of Lecture:


A few topics on which the speakers will share their valuable knowledge, are:

  • Advanced nutritional assessment

  • GI abnormalities and inflammation

  • GI testing and clinical pearls

  • Normal metabolism / methylation and sulphation abnormalities

  • Mitochondrial dysfunction and oxidative stress

  • Endocrine abnormalities

  • Reversible causes of autism

  • LDI as a treatment option for lyme

  • Update on new research findings


The Maps Spring Conference 2015 will see the speakers offering insight into innovative, new and different ways to treat different medical conditions. Attending the conference will prove to be highly beneficial for health practitioners, especially those in the field of ASD treatment.

Hits: 3055

Sartorius has attributed double-digit growth figures in 2014 to increased demand across the US for single use technologies.

The firm posted a 32% growth in sales across the region. For the full year, the international laboratory and process technology company reported sales across its business of 891 million Euros ($1.01bm).

This is up 13% on 2013. Sartorius’ bioprocess solutions division, which provides technologies and services to the biomanufacturing industry, generated 70% of the total revenues.

Group CEO, Joachim Kreuzburg, said “overall” 2014 had proved to be a “highly successful year” for the firm. “Our largest divisions, Bioprocess Solutions,” he added, “reported double-digit gains for the fourth year in succession and again proved to be the key growth driver for our company’s sales and earnings.

“The results for Lab Products & Services were still impacted by portfolio cleaning, as expected, but with the start of the new year, this is now behind us.”

Bioprocess solutions stimulating the growth

Inga Stucke, a spokesperson for Sartorius, said the growth had been led by its bioprocess solutions unit.

“Demand for single use products was high across our entire product range,” Ms Stucke said in comments to “It came from our fluid management products such as single use bags, filters and also from single use fermenters.”

For 2015, Ms Stucke predicted additional growth in its bioprocess division in the range of 5-8%.

In related news, Sartorius has just completed the sale of its Industrial Technologies Division to the Japanese Minebea Co Ltd. The move is designed to free up more time and resources for Sartorius to direct towards bioprocessing and laboratory equipment.

Related reading:

Hits: 1078
0 Lumiprobe fluorescent reagents

Inside this newsletter
  • Useful for Manufacturing Oligonucleotide Therapeutics
  • Citations of Interest
  • Scientist's Questions - Increase your knowledge and ideas!
  • Lumiprobe New Years greeting!

Lumiprobe reagents reduce cost, increase productivity and improve quality of research and production. Thanks to all ! Save 5% use discount code: biocrowd

Lumiprobe offers over 80 reagents for peptide, oligonucleotide, amine, alkyne binding - useful for Manufacturing Oligonucleotide Therapeutics!

In 2014, whether researching, creating, or manufacturing new drugs and treatment, Lumiprobe reagents were giving results in drug development research. Click chemistry was used with peptide-based nanoparticles in vivo, comparing the advantages between linear and cyclic peptides for intracellular delivery, process improvements for the economic  production,  peptide characterization , detecting and controlling oligonucleotide impurities, and exploring the development of peptides for diagnostic applications.  Novel oligonucleotide and peptide therapies were also enhanced when Lumiprobe's reagents were included.

Dye NHS esters - amine-reactive cyanine activated esters for the labeling of proteins, peptides, and other molecules

Sulfo NHS esters - water soluble sulfo-Cyanine3 SE activated ester for amino-biomolecule labeling.

Azides - fluorescent biomolecule labeling through Click Chemistry

Alkynes -
alkyne dye,  Useful for both copper-catalyzed, and copper-free Click Chemistry.

Maleimides -
bright and photostable thiol-reactive dye for protein labeling

Amines - fluorophores with free amino group (amino-dye). It can be conjugated with NHS esters, alkynes, carboxy groups (after activation), and epoxides.

Hydrazides -
dyes with a reactivity for carbonyl groups (aldehydes and ketones) activated by acid.  It can be used for the labeling of glycoproteins (i.e. antibodies) after periodate oxidation of sugar moieties.

Citations of Interest !

Would you like your paper featured on Lumiprobe citation webpage?
Over 100 papers sorted by date or reagent are available for your review.
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

In Site-Selective Protein Immobilization by Covalent Modification of GST Fusion Proteins.
Zhou, Y.; Guo, T.; Tang, G.; Wu, H.; Wong, N.-K.; Pan, Z.
Bioconjugate Chemistry, 2014 doi: 10.1021/ bc50 0347b

The immobilization of functional proteins onto solid supports using affinity tags is an attractive approach in recent development of protein microarray technologies. Among the commonly used fusion protein tags, glutathione S-transferase (GST) proteins have been indispensable tools for protein–protein interaction studies and have extensive applications in recombinant protein purification and reversible protein immobilization. Here, by utilizing pyrimidine-based small-molecule probes with a sulfonyl fluoride reactive group, we report a novel and general approach for site-selective immobilization of Schistosoma japonicum GST (sjGST) fusion proteins through irreversible and specific covalent modification of the tyrosine-111 residue of the sjGST tag. As demonstrated by sjGST-tagged eGFP and sjGST-tagged kinase activity assays, this immobilization approach offers the advantages of high immobilization efficiency and excellent retention of protein structure and activity.

EGF receptor-targeting peptide conjugate incorporating a near-IR fluorescent dye and a novel 1,4,7-triazacyclononane-based 64Cu(II) chelator assembled via click chemistry.
Viehweger, K.; Barbaro, L.; Garcia, KP; Joshi, T.; Geipel, G.; Steinbach, J.; Stephan, H.; Spiccia, L.; Graham, B. Bioconjugate Chem., 2014, 25(5), 1011–1022. doi: 10.1021/ bc50 01388

A new Boc-protected 1,4,7-triazacyclononane (TACN)-based pro-chelator compound featuring a “clickable” azidomethylpyridine pendant has been developed as a building block for the construction of multimodal imaging agents. Conjugation to a model alkyne (propargyl alcohol), followed by deprotection, generates a pentadentate ligand, as confirmed by X-ray crystallographic analysis of the corresponding distorted square-pyramidal Cu(II) complex. The ligand exhibits rapid 64Cu(II)-binding kinetics (>95% radiochemical yield in <5 min) and a high resistance to demetalation. It may thus prove suitable for use in 64Cu(II)-based in vivo positron emission tomography (PET). The new chelating building block has been applied to the construction of a bimodal (PET/fluorescence) peptide-based imaging probe targeting the epidermal growth factor (EGF) receptor, which is highly overexpressed on the surface of several types of cancer cells. The probe consists of a hexapeptide sequence, Leu-Ala-Arg-Leu-Leu-Thr (designated “D4”), followed by a Cys-β-Ala-β-Ala spacer, then a β-homopropargylglycine residue with the TACN-based chelator “clicked” to its side chain. A sulfonated near-infrared (NIR) fluorescent cyanine dye (sulfo-Cy5) was introduced at the N-terminus to study the EGF receptor-binding ability of the probe by laser-fluorescence spectroscopy. Binding was also confirmed by coimmunoprecipitation methods, and an apparent dissociation constant (Kd) of ca. 10 nM was determined from radioactivity-based measurements of probe binding to two EGF receptor-expressing cell lines (FaDu and A431). The probe is shown to be a biased or partial allosteric agonist of the EGF receptor, inducing phosphorylation of Thr669 and Tyr992, but not the Tyr845, Tyr998, Tyr1045, Tyr1068, or Tyr1148 residues of the receptor, in the absence of the orthosteric EGF ligand. Additionally, the probe was found to suppress the EGF-stimulated autophosphorylation of these latter residues, indicating that it is also a noncompetitive antagonist.

Size- matched alkyne-conjugated cyanine fluorophores to identify differences in protein glycosylation.
Burnham- Marusich, A.R.; Plechaty, A.M.; Berninsone, P.M.
ELECTROPHORESIS, 2014, 35, 2621–2625. doi: 10.1002/elps.201400241

Currently, there are few methods to detect differences in posttranslational modifications (PTMs) in a specific manner from complex mixtures. Thus, we developed an approach that combines the sensitivity and specificity of click chemistry with the resolution capabilities of 2D-DIGE. In “Click-DIGE”, posttranslationally modified proteins are metabolically labeled with azido-substrate analogs, then size- and charge-matched alkyne-Cy3 or alkyne-Cy5 dyes are covalently attached to the azide of the PTM by click chemistry. The fluorescently-tagged protein samples are then multiplexed for 2DE analysis. Whereas standard DIGE labels all proteins, Click-DIGE focuses the analysis of protein differences to a targeted subset of posttranslationally modified proteins within a complex sample (i.e. specific labeling and analysis of azido glycoproteins within a cell lysate). Our data indicate that (i) Click-DIGE specifically labels azido proteins, (ii) the resulting Cy-protein conjugates are spectrally distinct, and (iii) the conjugates are size- and charge-matched at the level of 2DE. We demonstrate the utility of this approach by detecting multiple differentially expressed glycoproteins between a mutant cell line defective in UDP-galactose transport and the parental cell line. We anticipate that the diversity of azido substrates already available will enable Click-DIGE to be compatible with analysis of a wide range of PTMs.


Tech Support: Lumiprobe offers FREE tech support before or after you order.
Questions - Increase your knowledge and ideas!

I have few questions about the click-chemistry labeling and need suggestions. In the protocol for Click-Chemistry Labeling of Oligonucleotides and DNA,
1.  Triethylammonium acetate buffer (final concentration 0.2 M, pH 7.0) was used. Does it matter that types of salts and pH of buffer effect the labeling efficiency? Can PB buffer be used?
2.  Azide was dissolved in DMSO and 1.5 * (DNA concentration), is it OK that azide was dissolved in water? In my experiment, azide was connected to peptide and had a good water solubility. Is it 50% DMSO necessary for the performance of click-chemistry labeling?
3.  Degass steps were performed during the procedure. Does it sensitive to oxygen?
4.  Precipitating the conjugate with acetone or ethanol was preformed to remove excess small molecules. Can Amicon ultra 3K device (Millipore) for buffer changing get the same result?
5.  Can reaction yield get >90%? Will +4 Centigrade lower the yield?

Thank you for your email!

1. In practice, Click Chemisty displays little dependence on the composition of buffer. It should not contain free thiols (i.e. no DTT or mercaptoethanol). The reaction can be carried out at pH of at least 4 to 10. I believe phosphate will work fine.
2. You can dissolve your azide in water without any issues. The protocol uses DMSO because it is optimized for non water-soluble azides.
3. Yes, the reaction is sensitive to oxygen. Alkyne dimers can form upon oxidation. Moreover, hydroxyl radicals are formed upon oxidation of Cu(I) catalyst, and they can damage biomolecules, especially DNA/RNA. We recommend to degass the solution.
4. Any purification will work, precipitation is the easiest for oligo labeling. You can desalt the reaction.
5. Yes, yields may exceed 90%. Lowering temperature to +4 Centigrade will not harm, but probably will extend the required conjugation time.

Please do not hesitate to contact Lumiprobe if you have more questions.

Actually, I do have one more question about NHS-ester labeling. The optimal pH value for modification is 8.3-8.5. In most cases I saw, the pH value suggested is 7.4. For example, SDA (pierce, product 26167) I used for proteins labeling is used in PBS. Is there any difference between DNA labeling and protein labeling? The pKa value of primary amines is the key factor?

Optimal pH for NHS ester labeling is indeed 8.3-8.5. pH value of 7.4 can be used if you need to label preferably N-terminus of a protein rather than side chains of lysine. The terminal amino-group is less basic than lysine amine, and it is less protonated at this pH than that of lysine. Therefore, it reacts preferably with the NHS ester. At higher pH ranges, both amino groups are non-protonated, and since lysine amines are more reactive, they react first.

If you need to label protein lysines or aminolink-DNA, use pH 8.3-8.5.

Do you provide the service which conjugate peptide to cy5 NHS ester?

Unfortunately, Lumiprobe does not make labeled peptides and does not perform conjugation. However, Lumiprobe can supply you or service company of your choice with our fluorescent reagents. The labeling protocol is simple enough to be performed by you. If you have peptide purification facilities such as HPLC -  if you work with peptides, you likely have it). If you prefer labeling as a service, there are local companies who do it - Lumiprobe can supply our reagent to this company. This will help save money on reagents.

Why use Lumiprobe's fluorescent dyes such as Cyanine5 NHS ester?

Cyanine5 fluorophore emission has maximum in red region, where many CCD detectors have maximum sensitivity, and biological objects have low background. Dye color is very intense, therefore quantity as small as 1 nanomol can be detected in gel electrophoresis by naked eye.

* high quality,  ideal for very cost-efficient labeling
* works well in organic solvents for small molecule labeling of soluble proteins,
peptides and oligonucleotides
* Water-soluble sulfo-Cyanine 5 NHS ester for sophisticated cellular & protein targets
* Compatible with various instrumentation including fluorescent microscopes,
imagers, scanners, and fluorescence readers.


Send your tech questions ? Any comments on the newsletter? What information would you like in the next issue?

Lumiprobe New Year's greeting!
Restock your lab in January and save 5%.
Use discount code: biocrowd

Thank you for integrating Lumiprobe fluorescent probes into your work in 2014!
Restock your lab or begin a new project - Lumiprobe offers you a new year's email discount of 5%. Use discount code: biocrowd

If you need something not found in Lumiprobe's catalog - ask!

Lumiprobe offers to help with your research, and create a custom probe for you at no extra charge! Reagents can often be customized for your needs at price schedule similar to Lumiprobe's other reagents. Ask Lumiprobe's tech support - you'll receive attention to your research, and ideas on what or how to do the click chemistry reaction. Lumiprobe's website offers instantly downloadable Certificate of Analysis (CoA) detailing meticulous quality control, real NMR, UV and mass spectra, and HPLC chromatograms.

Lumiprobe |    Products/Technical Info |    Protocols |    Ordering |    Contact

Hits: 10289

Posted by on in Uncategorized

Single-use technologies have revolutionised the biopharmaceutical industries in more ways than you might think. It is indeed most common nowadays to see single use applications cascading along the many upstream and downstream processes which channel through the sector.

But what about the people who work tirelessly along the bioprocess supply chain? Well, it would seem Starbucks Japan has woken up and smelt the coffee when it comes to single use. The company’s outlets across East Asia are keeping  biopharmaceutical workers - along with the public - topped up on coffee which is brewed with a twist.

The art of great coffee

Starbucks Origami Personal Drip coffee is the first Starbucks single use drip coffee product offered in the world. Pick from one of three roasts, open the sealed bag, fan out the origami filter, affix to a mug and pour hot water over the ground beans.

Then sit back and enjoy the perfect blend.

Personal Drip, so says Starbucks, invokes the “artistry and hand-crafted nature of Japan’s ancient art of origami and this innovative product allows customers to brew a single cup of Starbucks coffee at home that does not require any special equipment”.

We’d have to agree. After all, at ALLpaQ we like to think of ourselves as coffee connoisseurs. Even so, this is by far the most creative way we’ve seen of brewing coffee.

Right then, time to put the kettle on. Anybody want one?


Related reading:

Hits: 753

Bioprocessing news: The global single use bioreactors market looks set to expand at a two-fold compound annual growth rate over the next five years, according to a report by Research and Markets.

Back in 2014, the single use bioreactor market generated $202.5 million. This, says the report, could grow 18.4% to reach $470.9 million by 2019.

A single use bioreactor – or disposable bioreactor – is a bioreactor which harnesses disposable bags rather than a culture vessel.

The market expansion of single use bioreactors is being driven by a number of factors including the increasing deployment of the technology in developing markets such as China and India.

Commercial single use bioreactors

Research and Markets’ report segments the global single use bioreactors by molecule type, type of cell, technology, end user and region.

On their website, they explain: “The monoclonal antibodies (MAbs) segment accounted for the lion’s share of the global SUB market, by molecule type. However, the stem cell segment is expected to grow at the highest CAGR in the forecast period, owing to an increased focus on research in this segment.

“On the basis of type of cell, the SUB market is categorized into mammalian cell, bacterial cell, yeast cell and others (insect cell and plant cell). The mammalian cell segment is expected to be the new revenue pocket in the market by type of cell. Increasing numbers of biologics are being based on mammalian cells due to their increased compatibility and bioactivity in humans.”

“The technology segment,” continues Research and Markets, “is subsegmented into wave-induced motion SUBs, stirred SUBs, single-use bubble column bioreactors and others (single-use reactors with vertically perforated discs and single-use hybrid reactors). Wave-induced motion SUB technology is the oldest and most widely accepted of these, which accounts for its large market share.

“Research and development (R&D) of biopharmaceutical manufacturers, research institutes and contract research organizations (CROs) are the major end users of the SUB, followed by biopharmaceutical manufacturing. The large share of the R&D segment can be attributed to the wide acceptance of SUBs for small – and mid-scale biopharmaceutical manufacturing for clinical testing and R&D. New and innovative product launches were found to be the dominant strategy adopted by key industry participants to increase their market share and cater to unmet market needs.”

Single use bioreactors: key report topics

Key topics areas covered in Research and Markets’ single use bioreactor report, include:

  1. 1. Introduction
  2. 2. Research Methodology
  3. 3. Executive Summary
  4. 4. Premium Insights
  5. 5. Market Overview
  6. 6. Industry Insights
  7. 7. Single Use Bioreactor Market, By Technology
  8. 8. Single Use Bioreactor Market, By Molecule Type
  9. 9. Single Use Bioreactor Market, By Type Of Cell
  10. 10. Single Use Bioreactor Market, By End User
  11. 11. Single Use Bioreactor Market, By Geography
  12. 12. Competitive Landscape
  13. 13. Company Profiles

Related reading:

Hits: 777


Hits: 460

Posted by on in Health

US bioprocess equipment maker, ABEC, has taken a step into the European market by purchasing a former electronic component plant in Cork, Ireland.

The facility, previously owned by French firm FCI, will become a producer of custom engineered bioprocess equipment for the clinical and commercial manufacturing of biopharmaceuticals.

Emily Smith, marketing coordinator at ABEC, said: “Similar to our US HQ, we will be able to engineer, design, manufacture, and test the entire bioprocess – upstream, downstream and ... keep reading ...

Hits: 449

Proprietors of single-use technology could be perfectly placed to play a leading role in the design and construction of biopharma facilities according to Kurt Gilson, western regional manager at Total Facility Solutions.

His comments come on the back of concerns expressed by a number of leading pharmaceutical companies about the increasing reliance on system vendors in the supply chain.

Mr Gilson, speaking to, downplayed such fears, underscoring greater flexibility and reduced costs as potential upsides if vendors were to play a more central role in the design of bioprocessing facilities.

“The use of disposable or single-use technology is dramatically changing plant design and construction,” he said.

“If the bioprocess manufacturing requirements align with the technology capabilities of the systems vendor, then the detailed design and construction of the plant by a systems vendor does not limit the plant flexibility any more than traditional delivery methods and could offer schedule and cost advantages.”

Back in October 2014, Sartorius Stedim Biotech received an award from the International Society for Pharmaceutical Engineering for the design of WuXi AppTec bulk cell culture production facility in China.

Even so, Mr Gilson said that in the current climate “few” equipment manufacturers had the “breadth of process technology to deliver complete systems including support utilities and cleanrooms”.

Total Facility Solutions is a subsidiary of engineering firm M+W.

Related reading:

Hits: 821

The global healthcare cold chain logistics market is poised to grow over the next five years, according to a report from research firm TechNavio.

Demand in developing economies for generic pharmaceutical products is driving an increased need for temperature-sensitive healthcare transportation.

TechNavio estimates a compound annual growth rate of 13.31% between 2014-2019 in the cold chain market.

Faisal Ghaus, the company’s vice president, commented: “Recently, there’s been an increase in the demand for temperature-sensitive pharmaceuticals, and this is expected to propel the demand for cold chain logistics in the coming years.”

Cold chain management refers to the logistical process used to maintain optimal conditions during the transport, storage and handling of products such as pharmaceuticals and chemicals.

Healthcare products often include vaccines and blood plasma, frozen pharmaceuticals and insulin.

Recent years have seen increased investment in healthcare infrastructure and technologies to match demand for the transportation and storage of temperature-sensitive cargo.

TechNavio’s 200 global analysts develop over 2000 pieces of research every year.

Related reading:

Hits: 795

Posted by on in Health

Reckitt Benckiser, the owner of household brands such as Cillit Bang, Vanish and Nurofen, has completed the demerger of its pharmaceutical unit.

Shareholders agreed the move earlier in December. The new division, Indivior PLC, has been listed as a separate company on the London Stock Exchange.

Reckitt chief executive, Rakesh Kapoor, wished the Indivior PLC well, saying the separation would enable both businesses to “focus on their core competencies”.

“Reckitt will continue to pursue its strategy of being a global leader in the health, hygiene and home categories,” commented Mr Kapoor.

The demerger has triggered a drop in Reckitt shares, down 60p to £52.50. Indivior PLC currently resides at 145p.

Reckitt Benckiser launched the strategic review of its pharmaceutical business back in October 2013. A large portion of its drug sales derive from Suboxone – a product used to treat dependence on heroin and other opiates.

Reckitt Benckiser said the review left little doubt that “the demerger is in the best interests of RB shareholders”.

Related reading:

Hits: 674

Posted by on in Health

Remember when you were at school and the teachers were always going on about the three “Rs” and how important they were – Reading, ‘Riting and ‘Rithmetic. Get them right, they said, and everything else would follow.

We couldn’t agree more. In fact, when it comes to bioprocess containment, we have our own take on the three ‘Rs’. They’re incorporated into our brand ethic:

Re-use: Our containers can be re-used many times and individual panels replaced if necessary

Return: We’re happy to accept containers returned from our customers

Recycle: ALLpaQ bioprocess containers are manufactured from recyclable plastic

Ok, we know you probably don’t like sums, but here’s one anyway:

ALLpaQ’s three ‘Rs’ = less plastic in landfill + lower oil and energy consumption + reduced Co2 carbon emissions.

That’s it, bioprocess containment lesson over. Class dismissed!

Related reading:

Hits: 566

As a young man, mother would always tell me to “clean your room, son”. Fastforward a decade – or two or three – and the occasional pot or pan still lurks under the bed. Mother, I apologise.


When it comes to manufacturing and scientific research though, cleanliness is a must.

Keeping your cleanroom “clean” is imperative – the nostalgic teenage kick of sweeping things under the carpet has no place here.

Your cleanroom, after all, must only be occupied by a controlled level of contamination.

Ensuring any cleanroom facility is equipped with the right tools is therefore a must.

Bioprocessing cleanroom particle containment

The ALLpaQ Cleanroom 1000 bioprocess container is a bit of a clean freak. Obsessively compulsive about keeping unwanted particles at bay, the container delivers greater hygiene, cost effectiveness, functionality and versatility day in, day out.

Unlike steel equivalents, the ALLpaQ Cleanroom range is:

Got a question about cleaning your room?

ALLpaQ Cleanroom bioprocess containers have been developed for specific use within a cleanroom environment.

Find out more

Hits: 518

American drug giant Merck is reportedly eying up a possible acquisition of the biopharmaceuticals company Cubist Pharmaceuticals.

The deal, according to the New York Times, could be announced as early as next week. Merck could pay around $100 a share in a move which would value the US antibiotics maker in the range of $7.5 billion.

Cubist, which makes drugs to treat dangerous bacteria and superbugs in the developing world, has seen its share value nearly double over the last two years.

Should the deal go through it would mark the latest in a long line of multibillion-dollar pharmaceutical mergers and acquisitions.

Merck, one of America’s largest makers of vaccines, prescription products and oncology treatments, has a market value in excess of $174 billion.

Related reading:

Hits: 567

Please note: spoiler alert. Star Wars: The Force Awakens. New character revealed.

Star Wars: The Force Awakens lit up the websphere last week with the release of its first teaser trailer. So what did we learn? Among the quick shots of various characters emerged a strange new droid, a badass lightsaber, the Millennium Falcon and mysterious voice over.

Here’s something the Star Wars trailer didn’t reveal. Through means as powerful as the Force we’ve just come across some interesting fresh character news.

The mysterious new character goes by the name of Genesis 1000. These are the key plot points we know about Genesis 1000:

Continue reading for plot reveals and character photos


Hits: 501

Most Featured Blogs

Most Viewed Blogs